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2008-2009 Influenza Season 
Week 19 ending May 16, 2009 
All data are preliminary and may change as more reports are received. 
(Due to the response to the novel influenza A (H1N1) investigation, surveillance regions were 
changed from Census Divisions to Department of Health and Human Services (HHS) Regions.) 
 
Synopsis:  During week 19 (May 10 - 16, 2009), influenza activity decreased in the United States, 
however there are still higher levels of influenza-like illness than is normal for this time of year.   
o One thousand seventy-four (15.1%) specimens tested by U.S. World Health Organization 
(WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) 
collaborating laboratories and reported to CDC/Influenza Division were positive for 
influenza. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was below the 
epidemic threshold.  
o Two influenza-associated pediatric deaths were reported. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below the national 
baseline.  One of the ten surveillance regions reported ILI above their region-specific 
baselines. 
o Five states reported geographically widespread influenza activity, 13 states reported 
regional activity, the District of Columbia and 15 states reported local influenza activity; 16 
states reported sporadic influenza activity, and one state reported no influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) Novel A H1N1
A  
(could 
not be 
sub-
typed)¥ 
A 
 (Un-
sub-
typed) 
B  Pediatric Deaths 
Nation Normal 15.1% 18 of 51  7,413 1,812 2,649 400 11,687 9,969 61 
Region I Elevated 10.9% 3 of 6 523 137 210 13 1,080 798 1 
Region II Normal 16.7% 2 of 2 267 107 135 13 1,057 706 8 
Region III Normal 13.3% 2 of 6 1,152 157 149 52 614 1,338 9 
Region IV Normal 10.1% 4 of 8 800 76 68 31 1,620 1,152 6 
Region V Normal 18.2% 1 of 6 1,600 160 1,444 105 478 1,271 9 
Region VI Normal 4.8% 2 of 5 716 94 91 1 3,936 2,427 12 
Region VII Normal 13.0% 0 of 4 490 44 89 122 445 525 0 
Region VIII Normal 8.4% 0 of 6 465 196 68 45 1,397 484 5 
Region IX Normal 36.1% 4 of 4 1,043 589 288 13 744 616 10 
Region X Normal 28.6% 0 of 4 357 252 107 5 316 652 1 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, 
FL, GA, KY, MS, NC, SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, 
SD, UT, WY; Region IX: AZ, CA, Guam, HI, NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states and the District of Columbia 
¥ >99% of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are novel A (H1N1) influenza viruses upon further testing 
 
2008-2009 Influenza Season – Week 19, ending May 16, 2009           
 
 2
 
U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 15 and 17, 2009, CDC confirmed that two cases of febrile respiratory illness 
occurring in children who reside in adjacent counties in southern California were caused by 
infection with a novel influenza A (H1N1) virus. As of May 22, 2009, 6,552 confirmed infections with 
novel influenza A (H1N1) virus have been identified by CDC and state and local public health 
departments.  Reporting of novel influenza A (H1N1) viruses by U.S. WHO collaborating 
laboratories began during week 17.  The results of tests performed during the current week are 
summarized in the table below. 
 
 Week 19 
No. of specimens tested 7,127 
No. of positive specimens (%) 1,074 (15.1%) 
Positive specimens by type/subtype  
Influenza A              1,026 (95.5%) 
        A (H1)           66 (6.4%) 
        A (H3)           80 (7.8%) 
        A (unsubtyped)         101 (9.8%) 
        A (could not be subtyped)                       37 (3.6%) 
        A (novel influenza H1N1)                     742 (72.3%) 
Influenza B                  48 (4.5%) 
 
During week 19, seasonal influenza A (H1), A (H3), and B viruses continue to co-circulate with 
novel influenza A (H1N1).  Approximately 73% of all influenza viruses being reported to CDC are 
novel influenza A (H1N1) viruses. 
 
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories may be due in part to changes in testing practices by healthcare 
providers, triaging of specimens by public health laboratories, an increase in the number of 
specimens collected from outbreaks, and other factors. 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antigenic Characterization:  CDC has antigenically characterized 1,368 seasonal human 
influenza viruses [827 influenza A (H1), 140 influenza A (H3) and 401 influenza B viruses] collected 
by U.S. laboratories since October 1, 2008. 
All 827 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  All 140 influenza A (H3N2) viruses are related 
to the A (H3N2) vaccine component (A/Brisbane/10/2007).      
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Fifty-eight influenza B viruses tested belong to the 
B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 343 
viruses belong to the B/Victoria lineage and are not related to the vaccine strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference 
ferret antisera and results may not correlate with clinical protection against circulating viruses 
provided by influenza vaccination. 
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Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of novel influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 893 seasonal influenza A (H1N1), 145 influenza A 
(H3N2), and 444 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Eight hundred seventy-six seasonal influenza A (H1N1) and 
145 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  One hundred twenty-eight novel influenza A (H1N1) viruses have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  Ninety-six novel influenza A 
(H1N1) viruses have been tested for resistance to the adamantanes (amantadine and rimantadine).  
The results of antiviral resistance testing performed on these viruses are summarized in the table 
below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 893 888 (99.4%) 0 (0) 876 4 (0.5%) 
Influenza A (H3N2) 145 0 (0) 0 (0) 145 145 (100%) 
Influenza B 444 0 (0) 0 (0) N/A* N/A* 
Novel Influenza A  
(H1N1) 128 0 (0) 0 (0) 96 96 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with 
confirmed, probable or suspected cases of novel influenza A (H1N1) virus infection who are 
hospitalized or who are at higher risk for seasonal influenza complications.  The novel influenza A 
(H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and 
oseltamivir.  It is resistant to the adamantane antiviral medications, amantadine and 
rimantadine. Additional information on antiviral recommendations for treatment and 
chemoprophylaxis of novel influenza A (H1N1) infection is available at 
http://www.cdc.gov/h1n1flu/recommendations.htm 
 
In areas that continue to have seasonal influenza activity, especially those with circulation of 
oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use 
either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide 
adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human 
influenza A (H1N1) virus infection. 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 19, 6.7% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is 
below to the epidemic threshold of 7.3% for week 19. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 5/16/2009 
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Influenza-Associated Pediatric Mortality:  Two influenza-associated pediatric deaths were 
reported to CDC during week 19 (Arizona); one was due to influenza A virus (rapid test positive) 
and one was due to influenza B virus infection.  The deaths reported this week occurred between 
April 12 and April 25, 2009.  Since September 28, 2008, CDC has received 61 reports of influenza-
associated pediatric deaths that occurred during the current season.   
 
Of the 31 children who had specimens collected for bacterial culture from normally sterile sites, 13 
(41.9%) were positive; Staphylococcus aureus was identified in eight (61.5%) of the 13 children.  
Three of the S. aureus isolates were sensitive to methicillin and five were methicillin resistant.   
Twelve of the 13 children with bacterial coinfections were five years of age or older and 10 (76.9%) 
of the 13 children were 12 years of age or older.  An increase in the number of influenza-associated 
pediatric deaths with bacterial coinfections was first recognized during the 2006-07 influenza 
season.  In January 2008, interim testing and reporting recommendations were released regarding 
influenza and bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2005-06 season to present 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
 
During October 12, 2008 to May 2, 2009, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. Because of case 
identification methods utilized in this study, there is a delay from the date of hospitalization to the 
date of report.  
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During October 1, 2008 – May 16, 2009, preliminary laboratory-confirmed influenza-associated 
hospitalization rates reported by the EIP for children aged 0-4 years and 5-17 years were 3.7 per 
10,000 and 0.7 per 10,000, respectively.  For adults aged 18-49 years, 50-64 years, and ≥ 65 
years, the rates were 0.4 per 10,000, 0.5 per 10,000, and 1.5 per 10,000, respectively. 
 
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates,  
2008-09 and Previous Three Seasons 
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Outpatient Illness Surveillance: Nationwide during week 19, 1.7% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
0
1
2
3
4
5
6
7
40 42 44 46 48 50 52 1 3 5 7 9 11 13 15 17 19
Week
%
 o
f V
is
its
 fo
r I
LI
 
2006-07* 2007-08* 2008-09 National Baseline
 
 
On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 2.8%. One of the 
ten surveillance regions reported an ILI percentage above their region specific baseline.  ILI 
decreased during week 19 in 8 of 10 regions compared to week 18.  In regions 1 and 2, following a 
decrease in the percentage of visits for ILI during week 18, ILI increased during week 19. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and novel influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 19, the following influenza activity was reported: 
? Widespread influenza activity was reported by five states (Arizona, California, New Jersey, 
Texas, and Virginia). 
? Regional influenza activity was reported by 13 states (Alabama, Connecticut, Georgia, 
Hawaii, Illinois, Massachusetts, Nevada, New Hampshire, New Mexico, New York, 
Pennsylvania, South Carolina, and Tennessee). 
? Local influenza activity was reported by the District of Columbia and 15 states (Alaska, 
Colorado, Florida, Kansas, Louisiana, Maine, Maryland, Michigan, North Carolina, 
Oklahoma, Oregon, Rhode Island, Utah, Washington, and Wisconsin). 
? Sporadic activity was reported by 16 states (Arkansas, Delaware, Idaho, Indiana, Iowa, 
Kentucky, Minnesota, Mississippi, Missouri, Montana, Nebraska, North Dakota, Ohio, South 
Dakota, Vermont, and Wyoming). 
? No influenza activity was reported by one state (West Virginia). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: May 22, 2009.  
 
